Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Context Therapeutics Inc. CNTX

Healthcare  —  Biotechnology
0.35 (0.02) (5.41%) as of 25 Sep
Market cap
$34.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Context Therapeutics Inc. (CNTX) Business Profile

Updated before January 2025

Company Overview

Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for hormone-driven cancers. Founded in 2015 and headquartered in Philadelphia, Pennsylvania, CNTX focuses on addressing unmet medical needs in oncology, particularly for patients with limited treatment options. The company was co-founded by Martin Lehr, who serves as the Chief Executive Officer, and has a leadership team comprising experienced professionals in the biopharmaceutical industry. Their collective expertise spans drug development, clinical research, and commercialization, positioning CNTX as a key player in the fight against hormone-driven cancers.

Core Business Segments

Hormone-Driven Cancer Therapies

CNTX specializes in the development of therapies targeting hormone-driven cancers, such as breast, ovarian, and endometrial cancers. The company’s pipeline includes:

  • ONA-XR (Onapristone Extended Release): A selective progesterone receptor antagonist designed to block the activity of progesterone, a hormone that plays a critical role in the progression of certain cancers. ONA-XR is currently in clinical trials for hormone receptor-positive breast cancer and other solid tumors.

  • Combination Therapies: CNTX is exploring the potential of combining ONA-XR with other cancer treatments, such as immune checkpoint inhibitors and targeted therapies, to enhance efficacy and improve patient outcomes.

Research and Development Services

In addition to its proprietary drug pipeline, CNTX collaborates with academic institutions, research organizations, and pharmaceutical companies to advance the understanding of hormone-driven cancers. These partnerships enable the company to leverage cutting-edge science and accelerate the development of innovative therapies.

Business Model

CNTX operates on a research-driven business model that integrates drug discovery, clinical development, and strategic partnerships. The company generates revenue through licensing agreements, milestone payments, and potential royalties from its proprietary therapies. By focusing on hormone-driven cancers, CNTX addresses a niche market with significant unmet needs, positioning itself as a leader in this specialized field.

The company’s approach emphasizes:

  • Innovation: Developing first-in-class and best-in-class therapies for hormone-driven cancers.
  • Collaboration: Partnering with leading institutions and companies to enhance research capabilities and expand its therapeutic pipeline.
  • Patient-Centricity: Prioritizing the needs of patients by focusing on therapies that improve quality of life and survival rates.

Strategic Direction

CNTX is committed to advancing its clinical pipeline and expanding its therapeutic portfolio. Key strategic priorities include:

  • Advancing ONA-XR: Completing ongoing clinical trials and seeking regulatory approval for ONA-XR in multiple indications.
  • Expanding the Pipeline: Identifying and developing additional therapies targeting hormone-driven cancers and other oncology indications.
  • Global Expansion: Establishing a presence in international markets to broaden access to its therapies.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its operations and supply chain.

Competitive Landscape

CNTX operates in a competitive biopharmaceutical market, facing competition from both established companies and emerging startups. Key competitors include:

  • Pfizer Inc.: A global leader in oncology with a diverse portfolio of cancer therapies.
  • AstraZeneca: Known for its expertise in hormone-driven cancers, particularly breast and ovarian cancers.
  • Eli Lilly and Company: A major player in oncology with a focus on innovative therapies for hormone receptor-positive cancers.
  • Emerging Biotechs: Smaller companies developing novel therapies for hormone-driven cancers, such as Radius Health and Sermonix Pharmaceuticals.

CNTX differentiates itself through its focus on selective progesterone receptor antagonists and its commitment to addressing unmet medical needs.

Risk Factors

Like any biopharmaceutical company, CNTX faces several risks, including:

  • Clinical Trial Risks: The success of CNTX’s therapies depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s ability to commercialize its therapies.
  • Market Dependence: CNTX’s revenue is heavily reliant on the success of its lead candidate, ONA-XR.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing could delay product development and commercialization.
  • Competitive Pressure: The biopharmaceutical market is highly competitive, with rapid advancements in technology and science.

Recent Developments

In recent months, CNTX has made significant progress in advancing its clinical pipeline and corporate strategy:

  • Clinical Trials: The company announced positive interim results from its Phase 2 clinical trial of ONA-XR in hormone receptor-positive breast cancer.
  • Partnerships: CNTX entered into a collaboration with a leading academic institution to explore new combination therapies for hormone-driven cancers.
  • Corporate Milestones: The company successfully raised additional funding to support its research and development activities.

Global developments, such as the COVID-19 pandemic, have posed challenges to clinical trial enrollment and supply chain operations. However, CNTX has implemented measures to mitigate these impacts and ensure continuity in its operations.

Investment Considerations

Strengths

  • Innovative Pipeline: CNTX’s focus on hormone-driven cancers and its lead candidate, ONA-XR, position the company as a leader in this niche market.
  • Experienced Leadership: The management team’s expertise in oncology and drug development enhances the company’s ability to execute its strategic goals.
  • Collaborative Approach: Partnerships with academic institutions and pharmaceutical companies provide access to cutting-edge science and resources.

Risks

  • Clinical and Regulatory Uncertainty: The success of CNTX’s therapies depends on the outcomes of clinical trials and regulatory approvals.
  • Market Competition: The company faces competition from established players and emerging biotechs in the oncology space.
  • Financial Dependence: As a clinical-stage company, CNTX relies on external funding to support its operations and may face challenges in securing additional capital.

Conclusion

Context Therapeutics Inc. is a promising biopharmaceutical company with a strong focus on hormone-driven cancers. Its innovative pipeline, experienced leadership, and collaborative approach position it as a key player in the oncology market. While the company faces risks inherent to the biopharmaceutical industry, its strategic direction and commitment to addressing unmet medical needs provide a solid foundation for future growth. Investors should consider CNTX’s strengths and risks when evaluating it as a potential investment opportunity.